VIVSHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores VivoSim Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (11): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on VIVS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VIVS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, VivoSim Labs, Inc. returned −94.6% against +16.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 7% of US stocks
Cheaper than 93% of US stocks
Cheaper than 62% of US stocks
Higher than 5% of US stocks
Higher than 11% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
Higher than 5% of US stocks
Higher than 3% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
VivoSim Labs, Inc. has a market value of $3.2M and an enterprise value of $1.6M.
Revenue in the twelve months to 30 June 2026: $112K. The latest quarter shrank 51.4% year on year.
Net income over the same four quarters: −$12.3M, a −11016.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$10.1M.
Trailing P/E: 0.5×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
VivoSim Labs, Inc. employs 15 people — $7K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own VivoSim Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
VivoSim Labs highlighted updated FDA regulations allowing greater use of non-animal testing methods, saying its human-relevant models are already helping lower drug costs.
Why it matters — The regulatory change and the company's stated use of human-relevant models are relevant to VIVS watchers tracking its role in non-animal safety testing.
VivoSim Labs presented new NAMkind™ drug toxicity data at EUROTOX 2026 in Vienna, highlighting long-term repeat-dose modeling, mechanistic GI barrier profiling, and the deconvolution of payload- and linker-dependent toxicities. The data reportedly demonstrates predictive superiority in liver and gastrointestinal safety across small molecules and antibody-drug conjugates.
Why it matters — The presentation signals advanced predictive capabilities in drug safety assessment, which could strengthen VIVS's position in the toxicity-modeling market.
VivoSim Labs announced it is adding a rat liver model to its NAMkind platform, a new cross-species capability designed to help pharmaceutical companies distinguish rat-specific liver toxicity from risks that may translate to humans.
Why it matters — This expands the platform's offerings to help drug developers better assess liver toxicity risk across species, potentially strengthening VivoSim's value proposition in preclinical safety testing.
VivoSim Labs announced it received notice from Nasdaq on August 4, 2026 that it regained compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. This followed a $5.0 million milestone payment from Eli Lilly and a $1.0 million escrow release, both tied to the prior sale of its FXR program.
Why it matters — Regaining compliance removes a near-term delisting risk for VIVS, which was addressed through newly received funds from its Eli Lilly FXR program transaction.
As at 8 Oct 2026, VivoSim Labs, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
No analyst covering VivoSim Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIVS are extrapolating price history, which says nothing about the business.
VivoSim Labs, Inc. returned -94.6% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
VivoSim Labs Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine.
The most recent item we track (GlobeNewsWire, 7 Oct 2026): "VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods". VivoSim Labs highlighted updated FDA regulations allowing greater use of non-animal testing methods, saying its human-relevant models are already helping lower drug costs.
VivoSim Labs Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The company provides human-relevant toxicology insights through its new approach methodologies, including customizable NAMkind™ models designed to evaluate liver toxicity, intestinal toxicity, permeability, and related drug properties. VivoSim Labs also supports investigational toxicology, mechanism-of-action studies, predictive screening, and research services for pharmaceutical and biotechnology partners at different stages of drug development. Based in San Diego, California, VivoSim Labs plays a specialized role in preclinical testing by using complex human tissue systems to help researchers study drug behavior in a more biologically relevant environment.
15 employees · United States · https://vivosim.ai
